Daniel

@dahisdaniel

Researcher @Biodevek | Ph.D. at @AzhariLab (@technion) and @Artzilab (@harvardmed) - Using biomedical engineering to improve human life

Joined July 2009

2.3K Following

489 Followers

195 Posts

dahisdaniel retweeted

Dr. Robert F. Siegmund, MBA

@robertfsiegmund

13 days ago

ASCO 2026 HIGHLIGHTS #ASCO26 delivered a striking mix of practice-changing late-stage data, long-term follow-up, molecularly guided treatment strategies and rare-tumor studies that would once have struggled to attract this level of attention. I used @Larvol CLIN data to identify the ten most exciting trial results. Here they are: RASolute 302: daraxonrasib in metastatic pancreatic cancer RASolute 302 was arguably the most important single therapeutic readout at ASCO 2026. Daraxonrasib, a multi-selective RAS(ON) inhibitor, was tested in previously treated metastatic pancreatic ductal adenocarcinoma. The trial showed median overall survival of 13.2 months with daraxonrasib versus 6.7 months with chemotherapy, corresponding to a 60% reduction in the risk of death. Reuters also reported tumor shrinkage or disappearance in more than 30% of treated patients, compared with about 10% on chemotherapy. This is strategically important because pancreatic cancer has long been one of the most difficult tumors to treat, and RAS has historically been considered hard to drug. If approved, daraxonrasib could become a major new treatment option and a platform asset for earlier-line and combination strategies. CROWN: LORBRENA in first-line ALK-positive advanced NSCLC The seven-year CROWN update is one of the strongest long-term targeted therapy datasets in advanced solid tumors. In previously untreated ALK-positive advanced or metastatic NSCLC, LORBRENA showed a 55% probability of remaining alive without disease progression at seven years, compared with 3% for crizotinib. Median progression-free survival was still not reached, with a hazard ratio of 0.19, representing an 81% reduction in the risk of progression or death. Pfizer also reported a 94% reduction in the risk of intracranial progression. The strategic meaning is clear: for some molecularly defined lung cancers, long-term disease control is now a realistic expectation. The CROWN data also reinforce the commercial value of CNS penetration and durable intracranial control in ALK-positive NSCLC. HARMONi-6: ivonescimab plus CT in first-line squamous NSCLC HARMONi-6 is important because it was not simply another chemo-immunotherapy trial. Ivonescimab, a PD-1/VEGF bispecific antibody, plus chemotherapy was compared directly with tislelizumab plus chemotherapy in previously untreated advanced squamous NSCLC. The study showed median overall survival of 27.89 months versus 23.69 months, with a hazard ratio of 0.66. The 24-month overall survival rates were 64.7% versus 48.6%. This matters because the comparator was an active PD-1 plus chemotherapy regimen, not chemotherapy alone. If confirmed in global studies, HARMONi-6 could challenge the current PD-1/chemotherapy paradigm and accelerate interest in PD-1/VEGF bispecific antibodies. PROTEUS: ERLEADA before/after surgery in high-risk localized PC PROTEUS tested perioperative ERLEADA plus androgen deprivation therapy in newly diagnosed high-risk localized or locally advanced prostate cancer undergoing radical prostatectomy. The trial met both primary endpoints. Pathological complete response or minimal residual disease was 8.9% versus 1.0%, and metastasis-free survival improved with a hazard ratio of 0.80. Five-year metastasis-free survival was 78.2% versus 73.5%. Time to subsequent therapy was also extended to 74.2 months versus 41.5 months. This trial is important because it brings systemic intensification into the curative-intent surgical setting. The effect size is not spectacular, but the paradigm shift is meaningful: high-risk localized prostate cancer may need earlier systemic control, not only salvage treatment after recurrence. KEYNOTE-A39: PADCEV plus KEYTRUDA in 1L advanced urothelial cancer KEYNOTE-A39 / EV-302 confirmed the durability of PADCEV plus KEYTRUDA in previously untreated locally advanced or metastatic urothelial carcinoma. With 42.8 months median follow-up, median overall survival was 33.6 months with PADCEV plus KEYTRUDA versus 15.9 months with chemotherapy, with a hazard ratio of 0.53. The 3.5-year overall survival rate was 44.0% versus 24.6%. Objective response rate was 67.5% versus 44.2%, and complete response rate was 30.4% versus 14.5%. This is now one of the clearest examples of an antibody-drug conjugate plus immunotherapy combination replacing platinum chemotherapy as the central first-line standard. The long-term data strengthen confidence in durability, although neuropathy and treatment management remain important in real-world practice. LIBRETTO-432: RETEVMO in RET fusion-positive early-stage NSCLC LIBRETTO-432 extends precision oncology into curative-intent lung cancer. The study enrolled patients with resected stage IB-IIIA RET fusion-positive NSCLC and randomized them to adjuvant RETEVMO or placebo. The trial reported a statistically significant event-free survival benefit and is positioned alongside ADAURA in EGFR-mutant disease and ALINA in ALK-positive disease. The key strategic point is testing. If RET-targeted adjuvant therapy becomes standard, molecular profiling at diagnosis and resection becomes even more important. This is another example of the metastatic precision oncology model moving into early-stage disease. NATALEE: KISQALI plus endocrine therapy in HR+, HER2- early BC NATALEE continued to support adjuvant KISQALI plus a nonsteroidal aromatase inhibitor in HR-positive, HER2-negative early breast cancer. At a median follow-up of 55.4 months, the 36-month invasive disease-free survival rate was 90.8% with KISQALI versus 88.0% with aromatase inhibitor alone. The 60-month invasive disease-free survival rate was 85.5% versus 81.0%. The broader eligibility criteria included high-risk node-negative patients, where KISQALI showed a hazard ratio of 0.606. The commercial and clinical question is not whether CDK4/6 inhibition works in early breast cancer, but which patients should receive it. NATALEE broadens the addressable population, but also raises familiar questions around access, toxicity, treatment duration and patient selection. IMvigor011: TECENTRIQ guided by ctDNA in bladder cancer IMvigor011 is one of the most conceptually important trials on the list. In muscle-invasive bladder cancer after surgery, serial ctDNA testing was used to identify molecular residual disease. ctDNA-positive patients randomized to TECENTRIQ had median disease-free survival of 9.9 months versus 4.8 months with placebo, and median overall survival of 32.8 months versus 21.1 months. Persistently ctDNA-negative patients had excellent outcomes, with 88% disease-free survival at two years. This trial may prove influential beyond bladder cancer. It supports a future in which adjuvant therapy is not given simply because clinical risk is high, but because molecular residual disease is detected. That is a major shift in how oncology treatment could be personalized after curative-intent surgery. SARC041: VERZENIO in dedifferentiated liposarcoma SARC041 is notable because it is the first positive phase 3 trial ever reported in dedifferentiated liposarcoma. VERZENIO improved median progression-free survival to 9.7 months versus 1.5 months with placebo, with a hazard ratio of 0.38. Six-month progression-free survival was 60% versus 22%, and 12-month progression-free survival was 39% versus 13%. Median overall survival was not reached versus 25.5 months, with an overall survival hazard ratio of 0.55, despite high crossover from placebo to VERZENIO. The response rate was modest, but that is not the main point. In this disease, durable disease control is clinically meaningful. SARC041 may establish CDK4/6 inhibition as a real treatment option in a rare sarcoma subtype where systemic standards have been weak. KEYNOTE-564: KEYTRUDA in adjuvant clear-cell RCC KEYNOTE-564 remains one of the most important adjuvant immunotherapy datasets in kidney cancer. The trial evaluated KEYTRUDA after nephrectomy in patients with clear-cell renal cell carcinoma at increased risk of recurrence. Earlier analyses established KEYTRUDA as the first adjuvant regimen to significantly improve both disease-free survival and overall survival versus placebo after surgery. Reported outcomes include disease-free survival hazard ratio of 0.71 and overall survival hazard ratio of 0.66. At ASCO 2026, the focus shifted toward ctDNA analysis in KEYNOTE-564, exploring whether molecular residual disease could help identify patients at highest risk of recurrence and potentially refine adjuvant treatment decisions. This is strategically important because KEYNOTE-564 is no longer only a positive adjuvant immunotherapy trial. It is now part of the broader question of how to personalize adjuvant treatment in renal cell carcinoma. If ctDNA can help distinguish patients who truly need treatment from those who may be safely observed, it could reshape future trial design, treatment selection and health-economic modelling in kidney cancer. See attached Summary Table of Key Trial Results from ASCO 2026 Strategic interpretation Several patterns stand out. First, ASCO 2026 strongly reinforced the move into earlier disease. PROTEUS, LIBRETTO-432, NATALEE, IMvigor011 and KEYNOTE-564 all address treatment before overt metastatic relapse. The future oncology battleground is increasingly the prevention of recurrence, not only treatment after recurrence. Second, molecular selection is becoming embedded across the disease continuum. RET fusions in early NSCLC, ALK in metastatic NSCLC, ctDNA in bladder cancer and renal cell carcinoma, RAS in pancreatic cancer and CDK4 biology in liposarcoma all show the same direction of travel: treatment value depends on identifying the right patients at the right time. Third, ADCs and bispecific antibodies are now challenging major standards. PADCEV plus KEYTRUDA has transformed first-line urothelial cancer. Ivonescimab may challenge PD-1 plus chemotherapy in squamous NSCLC if global data confirm the China results. Fourth, rare tumors are no longer peripheral. SARC041 shows that prospective data in rare cancers can still change practice, even when the commercial story is smaller than in lung, breast, prostate or kidney cancer. © Robert F. Siegmund, PhD MBA | Life Code GmbH I deliver strategic insights and product forecasting models to biopharma companies across the product lifecycle. Reach out to me!

robertfsiegmund's tweet photo. ASCO 2026 HIGHLIGHTS

#ASCO26 delivered a striking mix of practice-changing late-stage data, long-term follow-up, molecularly guided treatment strategies and rare-tumor studies that would once have struggled to attract this level of attention.

I used @Larvol CLIN data to identify the ten most exciting trial results. Here they are:

RASolute 302: daraxonrasib in metastatic pancreatic cancer

RASolute 302 was arguably the most important single therapeutic readout at ASCO 2026. Daraxonrasib, a multi-selective RAS(ON) inhibitor, was tested in previously treated metastatic pancreatic ductal adenocarcinoma.

The trial showed median overall survival of 13.2 months with daraxonrasib versus 6.7 months with chemotherapy, corresponding to a 60% reduction in the risk of death. Reuters also reported tumor shrinkage or disappearance in more than 30% of treated patients, compared with about 10% on chemotherapy.

This is strategically important because pancreatic cancer has long been one of the most difficult tumors to treat, and RAS has historically been considered hard to drug. If approved, daraxonrasib could become a major new treatment option and a platform asset for earlier-line and combination strategies.

CROWN: LORBRENA in first-line ALK-positive advanced NSCLC

The seven-year CROWN update is one of the strongest long-term targeted therapy datasets in advanced solid tumors.

In previously untreated ALK-positive advanced or metastatic NSCLC, LORBRENA showed a 55% probability of remaining alive without disease progression at seven years, compared with 3% for crizotinib. Median progression-free survival was still not reached, with a hazard ratio of 0.19, representing an 81% reduction in the risk of progression or death. Pfizer also reported a 94% reduction in the risk of intracranial progression.

The strategic meaning is clear: for some molecularly defined lung cancers, long-term disease control is now a realistic expectation. The CROWN data also reinforce the commercial value of CNS penetration and durable intracranial control in ALK-positive NSCLC.

HARMONi-6: ivonescimab plus CT in first-line squamous NSCLC

HARMONi-6 is important because it was not simply another chemo-immunotherapy trial.

Ivonescimab, a PD-1/VEGF bispecific antibody, plus chemotherapy was compared directly with tislelizumab plus chemotherapy in previously untreated advanced squamous NSCLC. The study showed median overall survival of 27.89 months versus 23.69 months, with a hazard ratio of 0.66. The 24-month overall survival rates were 64.7% versus 48.6%.

This matters because the comparator was an active PD-1 plus chemotherapy regimen, not chemotherapy alone. If confirmed in global studies, HARMONi-6 could challenge the current PD-1/chemotherapy paradigm and accelerate interest in PD-1/VEGF bispecific antibodies.

PROTEUS: ERLEADA before/after surgery in high-risk localized PC

PROTEUS tested perioperative ERLEADA plus androgen deprivation therapy in newly diagnosed high-risk localized or locally advanced prostate cancer undergoing radical prostatectomy.

The trial met both primary endpoints. Pathological complete response or minimal residual disease was 8.9% versus 1.0%, and metastasis-free survival improved with a hazard ratio of 0.80. Five-year metastasis-free survival was 78.2% versus 73.5%. Time to subsequent therapy was also extended to 74.2 months versus 41.5 months.

This trial is important because it brings systemic intensification into the curative-intent surgical setting. The effect size is not spectacular, but the paradigm shift is meaningful: high-risk localized prostate cancer may need earlier systemic control, not only salvage treatment after recurrence.

KEYNOTE-A39: PADCEV plus KEYTRUDA in 1L advanced urothelial cancer

KEYNOTE-A39 / EV-302 confirmed the durability of PADCEV plus KEYTRUDA in previously untreated locally advanced or metastatic urothelial carcinoma.

With 42.8 months median follow-up, median overall survival was 33.6 months with PADCEV plus KEYTRUDA versus 15.9 months with chemotherapy, with a hazard ratio of 0.53. The 3.5-year overall survival rate was 44.0% versus 24.6%. Objective response rate was 67.5% versus 44.2%, and complete response rate was 30.4% versus 14.5%.

This is now one of the clearest examples of an antibody-drug conjugate plus immunotherapy combination replacing platinum chemotherapy as the central first-line standard. The long-term data strengthen confidence in durability, although neuropathy and treatment management remain important in real-world practice.

LIBRETTO-432: RETEVMO in RET fusion-positive early-stage NSCLC

LIBRETTO-432 extends precision oncology into curative-intent lung cancer.

The study enrolled patients with resected stage IB-IIIA RET fusion-positive NSCLC and randomized them to adjuvant RETEVMO or placebo. The trial reported a statistically significant event-free survival benefit and is positioned alongside ADAURA in EGFR-mutant disease and ALINA in ALK-positive disease.

The key strategic point is testing. If RET-targeted adjuvant therapy becomes standard, molecular profiling at diagnosis and resection becomes even more important. This is another example of the metastatic precision oncology model moving into early-stage disease.

NATALEE: KISQALI plus endocrine therapy in HR+, HER2- early BC

NATALEE continued to support adjuvant KISQALI plus a nonsteroidal aromatase inhibitor in HR-positive, HER2-negative early breast cancer.

At a median follow-up of 55.4 months, the 36-month invasive disease-free survival rate was 90.8% with KISQALI versus 88.0% with aromatase inhibitor alone. The 60-month invasive disease-free survival rate was 85.5% versus 81.0%. The broader eligibility criteria included high-risk node-negative patients, where KISQALI showed a hazard ratio of 0.606.

The commercial and clinical question is not whether CDK4/6 inhibition works in early breast cancer, but which patients should receive it. NATALEE broadens the addressable population, but also raises familiar questions around access, toxicity, treatment duration and patient selection.

IMvigor011: TECENTRIQ guided by ctDNA in bladder cancer

IMvigor011 is one of the most conceptually important trials on the list.

In muscle-invasive bladder cancer after surgery, serial ctDNA testing was used to identify molecular residual disease. ctDNA-positive patients randomized to TECENTRIQ had median disease-free survival of 9.9 months versus 4.8 months with placebo, and median overall survival of 32.8 months versus 21.1 months. Persistently ctDNA-negative patients had excellent outcomes, with 88% disease-free survival at two years.

This trial may prove influential beyond bladder cancer. It supports a future in which adjuvant therapy is not given simply because clinical risk is high, but because molecular residual disease is detected. That is a major shift in how oncology treatment could be personalized after curative-intent surgery.

SARC041: VERZENIO in dedifferentiated liposarcoma

SARC041 is notable because it is the first positive phase 3 trial ever reported in dedifferentiated liposarcoma.

VERZENIO improved median progression-free survival to 9.7 months versus 1.5 months with placebo, with a hazard ratio of 0.38. Six-month progression-free survival was 60% versus 22%, and 12-month progression-free survival was 39% versus 13%. Median overall survival was not reached versus 25.5 months, with an overall survival hazard ratio of 0.55, despite high crossover from placebo to VERZENIO.

The response rate was modest, but that is not the main point. In this disease, durable disease control is clinically meaningful. SARC041 may establish CDK4/6 inhibition as a real treatment option in a rare sarcoma subtype where systemic standards have been weak.

KEYNOTE-564: KEYTRUDA in adjuvant clear-cell RCC

KEYNOTE-564 remains one of the most important adjuvant immunotherapy datasets in kidney cancer.

The trial evaluated KEYTRUDA after nephrectomy in patients with clear-cell renal cell carcinoma at increased risk of recurrence. Earlier analyses established KEYTRUDA as the first adjuvant regimen to significantly improve both disease-free survival and overall survival versus placebo after surgery. Reported outcomes include disease-free survival hazard ratio of 0.71 and overall survival hazard ratio of 0.66.

At ASCO 2026, the focus shifted toward ctDNA analysis in KEYNOTE-564, exploring whether molecular residual disease could help identify patients at highest risk of recurrence and potentially refine adjuvant treatment decisions.

This is strategically important because KEYNOTE-564 is no longer only a positive adjuvant immunotherapy trial. It is now part of the broader question of how to personalize adjuvant treatment in renal cell carcinoma. If ctDNA can help distinguish patients who truly need treatment from those who may be safely observed, it could reshape future trial design, treatment selection and health-economic modelling in kidney cancer.

See attached Summary Table of Key Trial Results from ASCO 2026

Strategic interpretation

Several patterns stand out. First, ASCO 2026 strongly reinforced the move into earlier disease. PROTEUS, LIBRETTO-432, NATALEE, IMvigor011 and KEYNOTE-564 all address treatment before overt metastatic relapse. The future oncology battleground is increasingly the prevention of recurrence, not only treatment after recurrence.

Second, molecular selection is becoming embedded across the disease continuum. RET fusions in early NSCLC, ALK in metastatic NSCLC, ctDNA in bladder cancer and renal cell carcinoma, RAS in pancreatic cancer and CDK4 biology in liposarcoma all show the same direction of travel: treatment value depends on identifying the right patients at the right time.

Third, ADCs and bispecific antibodies are now challenging major standards. PADCEV plus KEYTRUDA has transformed first-line urothelial cancer. Ivonescimab may challenge PD-1 plus chemotherapy in squamous NSCLC if global data confirm the China results.

Fourth, rare tumors are no longer peripheral. SARC041 shows that prospective data in rare cancers can still change practice, even when the commercial story is smaller than in lung, breast, prostate or kidney cancer.

© Robert F. Siegmund, PhD MBA | Life Code GmbH

I deliver strategic insights and product forecasting models to biopharma companies across the product lifecycle. Reach out to me!

Daniel @dahisdaniel

2 months ago

Apenas lembrando que dado a quantidade de pessoas neurodivergentes na ciência é mais provável que autismo cause vacinas 👍 By Christopher Penn @cspenn

Daniel @dahisdaniel

3 months ago

@DrDominicNg Cant it just be that people who consume more meat are physically leaner hence meat consumption being only a surrogate for baseline health?

186

Daniel @dahisdaniel

5 months ago

https://t.co/scsU567BV6

Who to follow

Trying to make this world a better place. Assistant Professor at the Chemical Engineering Department, Technion- Israel Institute of Technology, Israel.

Yashwanth Nanda Kumar, Ph.D

@yashusxdcr

Inventing, building, and scaling ultrasound technologies that bridge science and patient care. Sr. Research Engineer at HistoSonics

Daniel @dahisdaniel

5 months ago

@NTFabiano Nicholas, you and I know that creatine can be a surrogate for physical activity. This would be a huge confounder when concluding that creatine prevents cancer.

833

Daniel @dahisdaniel

over 1 year ago

Easily one of the most promising papers of 2025! Triple neoadjuvant therapy for Glioblastoma keeps patient recurrence free for 17 months (and counting!!!) https://t.co/4dvX3M4QuK

203

dahisdaniel retweeted

The Jerusalem Post

@Jerusalem_Post

over 1 year ago

Eitan Horn's loved ones continue to campaign for the madrich's release from Hamas captivity. Read what they had to say about their abducted friend and youth leader. ✍️ @JoanMargulies https://t.co/Fzp3UegNof

dahisdaniel retweeted

Eric Topol

@EricTopol

over 1 year ago

From Nature's top 2024 photos https://t.co/joGaE7oiBU I like this one, standing on the shoulders of giants ;-)

283

36K

dahisdaniel retweeted

Eric Topol

@EricTopol

over 1 year ago

A few key points from new @AACR Cancer Report https://t.co/KfHiCTafM9 —40% are associated with modifiable risk factors —risk of alcohol consumption highlighted —13% known to be linked to viruses/bacteria

EricTopol's tweet photo. A few key points from new @AACR Cancer Report
https://t.co/KfHiCTafM9
—40% are associated with modifiable risk factors
—risk of alcohol consumption highlighted
—13% known to be linked to viruses/bacteria https://t.co/nqweBBhq16

387

158

151

52K

dahisdaniel retweeted

The Lancet

@TheLancet

almost 2 years ago

Nearly half of dementia cases could be prevented or delayed by tackling 14 risk factors starting in childhood, including two new risks—high cholesterol and vision loss, suggests new report from the Lancet Commission on dementia. Find out more ➡️ https://t.co/FmfDSNfQ9f

TheLancet's tweet photo. Nearly half of dementia cases could be prevented or delayed by tackling 14 risk factors starting in childhood, including two new risks—high cholesterol and vision loss, suggests new report from the Lancet Commission on dementia.

Find out more ➡️ https://t.co/FmfDSNfQ9f https://t.co/LrLXNvIi2X

857

397

226

325K

dahisdaniel retweeted

Eric Topol

@EricTopol

almost 2 years ago

New discovery in glioblastoma brain cancer: skull bone marrow immune cells niches are trying to fight the tumor https://t.co/48KushCUBc @NatureMedicine

EricTopol's tweet photo. New discovery in glioblastoma brain cancer: skull bone marrow immune cells niches are trying to fight the tumor
https://t.co/48KushCUBc
@NatureMedicine https://t.co/fpgxKSUiNt

276

28K

dahisdaniel retweeted

The Lancet

@TheLancet

almost 2 years ago

Current projections estimate 153 million people will be living with dementia by 2050. Nearly half of dementia cases could be prevented or delayed by tackling 14 risk factors starting in childhood, suggests new report from a standing Lancet Commission: https://t.co/ZFRBBbIfdZ

TheLancet's tweet photo. Current projections estimate 153 million people will be living with dementia by 2050.

Nearly half of dementia cases could be prevented or delayed by tackling 14 risk factors starting in childhood, suggests new report from a standing Lancet Commission: https://t.co/ZFRBBbIfdZ https://t.co/fRA8WYcUVH

840

461

384K

dahisdaniel retweeted

Eric Topol

@EricTopol

almost 2 years ago

The first tumor infiltrating lymphocytes (TILs) were FDA approved to treat refractory cancer (melanoma) this year. In the new issue @ScienceMagazine a rundown and perspective from the pioneer who worked on developing this living drug for >30 years https://t.co/C5KHWSHSu3

$EricTopol's tweet photo. The first tumor infiltrating lymphocytes (TILs) were FDA approved to treat refractory cancer (melanoma) this year. In the new issue @ScienceMagazine a rundown and perspective from the pioneer who worked on developing this living drug for >30 years https://t.co/C5KHWSHSu3 https://t.co/VoTw7rfRaX$

561

166

146

89K

dahisdaniel retweeted

Wyss Institute @wyssinstitute

about 2 years ago

.@NatalieArtzi's lab developed an adhesive hydrogel that can be sprayed or injected directly into the brain during surgery, enabling the local release of multiple drugs & nanoparticles to activate the immune system. #BrainCancerAwarenessMonth #TEDTalk https://t.co/utKhUEvJLd

dahisdaniel retweeted

Natalie Artzi @NatalieArtzi

about 2 years ago

Excited to share our collaborative work with @azzilab on a new potential treatment for Alopecia Areata and other autoimmune skin diseases. https://t.co/Gh4Qt5vwsD @NuriaPuigmal @NourKYounis1 @MIT_IMES @MassGenBrigham

dahisdaniel retweeted

Eric Topol

@EricTopol

about 2 years ago

Gliobastomas are among the most aggressive and fatal cancers. After marked success treating 10 dogs, a unique IV "onionized" mRNA/nanoparticle individualized vaccine induced a striking anti-tumor immune response https://t.co/36OBimFOAB @CellCellPress @UF

EricTopol's tweet photo. Gliobastomas are among the most aggressive and fatal cancers. After marked success treating 10 dogs, a unique IV "onionized" mRNA/nanoparticle individualized vaccine induced a striking anti-tumor immune response
https://t.co/36OBimFOAB @CellCellPress @UF https://t.co/I6PG3MaQ0q

469

357

228K

Daniel @dahisdaniel

about 2 years ago

Irs 50-50% currently! Please vote for us!

Natalie Artzi @NatalieArtzi

about 2 years ago

Tonight at midnight semifinals end. Please vote today to help us advance to the finals. 🙏

dahisdaniel retweeted

Natalie Artzi @NatalieArtzi

about 2 years ago

We need your vote (1x per day) to help us advance to the FINALS which takes place Sunday night. Vote for the Wyss Institute/BWH team developing a novel melanoma monitoring tool in Matchup #2. Thank you!

Daniel @dahisdaniel

about 2 years ago

We need your vote! Thank you for the support!

Wyss Institute @wyssinstitute

about 2 years ago

Vote for our melanoma treatment monitor publication from @NatalieArtzi and @BrighamWomens in the semi-final round of STAT Madness: https://t.co/RztbNfpTYW

260

Daniel @dahisdaniel

about 2 years ago

@wyssinstitute Lets go Wyss Team!!!

Daniel

@dahisdaniel

Who to follow

Last Seen Users on Sotwe

Trends for you

Most Popular Users